Filter By:
Viewing 1 to 2 (2 Total)



Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

A phase 1b/2 dose-escalation study of ARRY-382, an oral inhibitor of colony-stimulating factor-1 receptor (CSF-1R) in combination with pembrolizumab for the treatment of patients with advanced solid tumors

Wael A. Harb, et al.



AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics

A Phase 1 Study of ARRY-382, an Oral Inhibitor of Colony-stimulating Factor-1 Receptor (CSF1R), in Patients with Advanced or Metastatic Cancers

J. Bendell, et al.